Study on MAFLD-related Cirrhosis Prevention and Treatment Strategies

NCT06135584 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

1000

Enrollment

OTHER

Sponsor class

Conditions

Metabolic Dysfunction-associated Fatty Liver Disease
Cirrhosis

Interventions

DRUG: Pioglitazone metformin tablets
DRUG: Other drugs
OTHER: Drug-free

Sponsor

The Affiliated Hospital of Hangzhou Normal University